Imperfect biomarkers for adjuvant chemotherapy in early stage breast cancer with good prognosis

Publication date: Available online 14 December 2019Source: Social Science &MedicineAuthor(s): Catherine Bourgain, Lionel Pourtau, Chafika Mazouni, Martine Bungener, et Julia Bonastre
Source: Social Science and Medicine - Category: Psychiatry & Psychology Source Type: research

Related Links:

YKL-39 belongs to the evolutionarily conserved family of Glyco_18-containing proteins composed of chitinases and chitinase-like proteins. Chitinase-like proteins (CLPs) are secreted lectins that lack hydrolytic activity due to the amino acid substitutions in their catalytic domain and combine the functions of cytokines and growth factors. One of the major cellular sources that produce CLPs in various pathologies, including cancer, are macrophages. Monocytes recruited to the tumor site and programmed by tumor cells differentiate into tumor-associated macrophages (TAMs), which are the primary source of pro-angiogenic factors...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
This study is conducted to further evaluate the efficacy and safety of CDK4/6 inh ibitors for HR+ /HER2− ABC, and explore the prefer population through subgroup analysis.MethodWe identified relevant  randomized controlled trials that compared CDK4/6 inhibitors plus ET to ET alone in HR+ /HER2− ABC. We calculated the hazard ratios (HRs) for PFS and OS, and risk ratios (RRs) for objective response rate (ORR), clinical benefit rate (CBR), adverse events (AEs). Statistical analysis was perfo rmed with the random-effects model.ResultEight trials and 4580 patients were included in thi...
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
a Cho Resistance to chemotherapy and radiation therapy is considered a major therapeutic barrier in breast cancer. Cancer stem cells (CSCs) play a prominent role in chemo and radiotherapy resistance. The established chemo and radio-resistant triple-negative breast cancer (TNBC) cell line MDA-MB-231/IR displays greater CSC characteristics than the parental MDA-MB-231 cells. Escalating evidence demonstrates that metadherin (MTDH) is associated with a number of cancer signaling pathways as well as breast cancer therapy resistance, making it an attractive therapeutic target. Kaplan–Meier plot analysis revealed...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Objective: Changes in the number of various tumor-infiltrating lymphocytes (TILs) and degrees of vascular normalization in breast cancer (BC) patients after neoadjuvant chemotherapy (NAC) were analyzed to screen key factors that can predict the prognosis.Methods: HE-stained sections were used to assess the degree of TILs infiltration; immunohistochemically stained sections were used to assess the infiltration of CD8+, CD4+, FOXP3+ Tregs and the expression of PD-L1; immunofluorescence-stained sections were used to assess the microvessel density (MVD) and microvessel pericyte coverage index (MPI). The expression of them befo...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 21 January 2020Source: MethodsAuthor(s): Martina Sollini, Luca Cozzi, Gaia Ninatti, Lidija Antunovic, Lara Cavinato, Arturo Chiti, Margarita KirienkoAbstractThe aim of the present review was to assess the current status of positron emission tomography/computed tomography (PET/CT) radiomics research in breast cancer, and in particular to analyze the strengths and weaknesses of the published papers in order to identify challenges and suggest possible solutions and future research directions. Various combinations of the terms “breast”, “radiomic”, “PET”, &...
Source: Methods - Category: Molecular Biology Source Type: research
In conclusion, the addition of PPIs to the treatment regimen of breast cancer appears to be a promising strategy to potentiate the efficacy of chemotherapy and may suppress cancer metastasis. PMID: 31955147 [PubMed - in process]
Source: Acta Pharmaceutica - Category: Drugs & Pharmacology Authors: Tags: Acta Pharm Source Type: research
Abstract BACKGROUND: The Oncotype DX Breast Cancer Assay is a 21-gene assay used to predict the likelihood of distant recurrence and the benefit of chemotherapy in patients with node-negative, tamoxifen-treated breast cancer. Prior studies demonstrated 7-19% discordance, or a difference between the recurrence score (RS) and tumor grade (TG) in breast cancer patients. BRCA mutated tumors (BRCA+) have been shown to be associated with higher RS as compared to BRCA-negative patients (BRCA-). OBJECTIVES: We developed a large Oncotype RS database to determine if the BRCA mutation status is associated with discordan...
Source: Oncology - Category: Cancer & Oncology Authors: Tags: Oncology Source Type: research
Tumour-infiltrating lymphocytes (TILs) are an emerging biomarker in breast cancer (BC) [1].
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Editorial Source Type: research
ConclusionsA majority of IBC patients in our study presented with node-positive disease, and for those presenting with cN2-3 disease, more extensive axillary surgery is potentially associated with improved survival. For cN0 patients, however, more extensive axillary surgery was not associated with a survival benefit, suggesting an opportunity for more personalized care.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
Authors: Batoo S, Bayraktar S, Al-Hattab E, Basu S, Okuno S, Glück S Abstract With the introduction of anthracycline-based regimens, 5-year survival rates have significantly improved in patients with early-stage breast cancer. With the addition of trastuzumab, a monoclonal antibody targeting the human epidermal growth factor receptor-2 (HER2), improvements in overall survival have been observed among patients with advanced HER2-positive disease. Subsequently, lapatinib, an orally bioavailable small molecule dual HER2- and EGFR/HER1-specific tyrosine kinase inhibitor, received Food and Drug Administration (FDA)...
Source: Journal of Carcinogenesis - Category: Cancer & Oncology Tags: J Carcinog Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Psychology | Science